First-in-Human Results of Terbium-161 PSMA Radioligand Therapy in mCRPC: Insights from the VIOLET Study

[161Tb]Tb-PSMA-I&T, a dual beta- and Auger electron-emitting radioligand, was administered safely in men with metastatic castration-resistant prostate cancer (mCRPC), with no dose-limiting toxicities at doses up to 7.4 GBq.
Serious treatment-related adverse events were rare, and no grade 4 toxicities or treatment-related deaths occurred.
This first-in-human trial supports further investigation of terbium-161-based theranostics in advanced prostate cancer.

Specialty calculators

For clinical reference; use professional judgment.